The German biotech firm CureVac – currently carrying out one of the handful of worldwide clinical tests on a potential COVID-19 vaccine – is to receive 75 million euros (84.7 million dollars) in loans from the European Investment Bank (EIB).
The money is to help the company complete a production facility and support the development as well as mass production of a vaccine, EIB said in a statement on Monday.
“The only way to end the dramatic situation the world is facing since the outbreak of the COVID-19 pandemic would be a safe and effective vaccine,” EIB Vice-President Ambroise Fayolle said in the statement.
The European Commission, which is co-funding the loans using the EU long-term budget, said it would support CureVac after the U.S. reportedly approached the company to cut a deal on exclusive vaccine rights in March.
The White House never formally confirmed the reports, which unleashed a political backlash in Europe.
The German government announced in June that it would acquire a 300-million-euro stake in the firm.
CureVac, based in the south-western German city of Tuebingen, said it expects the first results of its clinical trial in August.